Yuan He

List of Publications by Year
in descending order

14 papers	285 citations	1040056 9 h-index	1125743 13 g-index
14 all docs	14 docs citations	14 times ranked	555 citing authors

#	Article	IF	Citations
1	CD20-selective inhibition of CD47-SIRPα "don't eat me" signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab. OncoImmunology, 2018, 7, e1386361.	4.6	58
2	Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction. OncoImmunology, 2016, 5, e1202390.	4.6	35
3	Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1α mediated XPC transcription. Oncogene, 2020, 39, 6893-6905.	5.9	30
4	CD47 Expression Defines Efficacy of Rituximab with CHOP in Non–Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL. Cancer Immunology Research, 2019, 7, 1663-1671.	3.4	28
5	Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis. Nature Communications, 2019, 10, 533.	12.8	26
6	A novel humanized Frizzled-7-targeting antibody enhances antitumor effects of Bevacizumab against triple-negative breast cancer via blocking Wnt/β-catenin signaling pathway. Journal of Experimental and Clinical Cancer Research, 2021, 40, 30.	8.6	23
7	A novel recombinant human Frizzled-7 protein exhibits anti-tumor activity against triple negative breast cancer via abating Wnt/β-catenin pathway. International Journal of Biochemistry and Cell Biology, 2018, 103, 45-55.	2.8	21
8	Melanoma-Directed Activation of Apoptosis Using a Bispecific Antibody Directed at MCSP and TRAIL Receptor-2/Death Receptor-5. Journal of Investigative Dermatology, 2016, 136, 541-544.	0.7	18
9	A CD47-blocking TRAIL fusion protein with dual pro-phagocytic and pro-apoptotic anticancer activity. British Journal of Haematology, 2014, 164, 304-307.	2.5	15
10	The Implementation of TNFRSF Co-Stimulatory Domains in CAR-T Cells for Optimal Functional Activity. Cancers, 2022, 14, 299.	3.7	11
11	Oroxylin A inhibits the migration of hepatocellular carcinoma cells by inducing NAG-1 expression. Acta Pharmacologica Sinica, 2022, 43, 724-734.	6.1	9
12	A versatile pretargeting approach for tumour-selective delivery and activation of TNF superfamily members. Scientific Reports, 2017, 7, 13301.	3.3	6
13	Development of Bispecific Antibody Derivatives for Cancer Immunotherapy. Methods in Molecular Biology, 2019, 1884, 335-347.	0.9	5
14	CD47 Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2018, 132, 2852-2852.	1.4	0